Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

FDA new drug approvals in Q1 2022

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 21, 329 (2022)


Updates & Corrections

  • Correction 20 April 2022: Suvorexant and and lemborexant were described as orexin receptor agonists rather than antagonists, and this has been corrected.

Competing Interests

The author declares no competing interests.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links